Erasca, Inc. (ERAS)
Nasdaq · Healthcare · Biotechnology
$14.72−0.14%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $5.1B
- 52-week range
- $2.11 – $24.28
- 52-week change
- +494.35%
- EPS (trailing)
- −$0.95
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$125M
- Diluted EPS
- −$0.44
- Free cash flow
- −$95.6M
From the company’s annual report on SEC EDGAR.
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc.
Headquarters: San Diego, United States · 103 employees · erasca.com